본문 바로가기

A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3Scopus Q3
저널
Biomolecules & Therapeutics23 · pp.434 · 2015
피인용
Web of Science 14KCI 1
JCR IF
JCR 2014 1.727
ISSN
1976-9148

저자

  1. Umasankar De제1저자성균관대학교
  2. Soma Kundu부산대학교
  3. Nabanita Patra부산대학교
  4. 안미영원광대학교
  5. 안지혜성균관 대학교
  6. 손지연성균관대학교
  7. 윤정현부산대학교
  8. 문형룡부산대학교
  9. 이병무성균관대학교
  10. 김형식교신저자성균관대학교

초록

Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. Similar to suberanilohydroxamic acid (SAHA); MHY219 inhibited HDAC1 enzyme activity in a dose-dependent manner. MHY219 cytotoxicity was higher in LNCaP (IC50=0.67 mu M) than in DU145 cells (IC50=1.10 mu M) and PC3 cells (IC50=5.60 mu M) after 48 h of treatment. MHY219 significantly inhibited the HDAC1 protein levels in LNCaP and DU145 cells at high concentrations. However, inhibitory effects of MHY219 on HDAC proteins levels varied based on the cell type. MHY219 significantly inhibited LNCaP and DU145 cells migration by down-regulation of matrix metalloprotease-1 (MMP-1) and MMP-2 and induction of tissue inhibitor of metalloproteinases-1 (TIMP-1). These results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and MMP-2, which is related to the reduction of HDAC1.

키워드

HDAC inhibitorMHY219MMPsMigrationProstate cancer

식별자

WoS UID
000360598300007
KCI
ART002019366